These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15737055)

  • 1. Pathologic quiz case: a large, ill-defined cystic breast mass. Invasive cystic hypersecretory duct carcinoma.
    Resetkova E; Padula A; Albarraccin CT; Sneige N
    Arch Pathol Lab Med; 2005 Mar; 129(3):e79-80. PubMed ID: 15737055
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytological findings in cystic hypersecretory ductal carcinoma of the breast: a potential pitfall in mammary cytology.
    Schmitt F; Tani E
    Cytopathology; 2000 Dec; 11(6):513-9. PubMed ID: 11194083
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnosing invasive cystic hypersecretory duct carcinoma of the breast with fine needle aspiration cytology. A case report.
    Lee WY; Cheng L; Chang TW
    Acta Cytol; 1999; 43(2):273-6. PubMed ID: 10097724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive cystic hypersecretory carcinoma of the breast: a rare variant of breast cancer: a case report and review of the literature.
    Sun J; Wang X; Wang C
    BMC Cancer; 2019 Jan; 19(1):31. PubMed ID: 30621638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cystic hypersecretory carcinoma with microinvasive carcinoma and cystic hypersecretory hyperplasia of breast: report of a case].
    Chen DB; Kan X
    Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):54-5. PubMed ID: 20388402
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cystic hypersecretory carcinoma: rare and potentially aggressive variant of intraductal carcinoma of the breast. Report of five cases].
    Skálová A; Ryska A; Kajo K; Kinkor Z
    Ceska Gynekol; 2005 Jan; 70(1):73-8. PubMed ID: 15779300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic features of cystic hypersecretory lesion of the breast].
    Bi R; Cheng Y; Yu B; Shui R; Yang W; Xu X
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):25-9. PubMed ID: 24713245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD31 with strong membrane-based immunoreactivity in ductal carcinoma of the breast.
    Ortiz-Hidalgo C; Torres JE; Cuesta-Mejías T; Mendoza-Ramón H
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):334-5. PubMed ID: 11127927
    [No Abstract]   [Full Text] [Related]  

  • 9. Cystic hypersecretory ductal carcinoma (CHDC): a rare distinctive variant of ductal carcinoma.
    DiPasquale A; Peiris L; Silverman S
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34289997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent primary angiosarcoma and invasive ductal carcinoma in the same breast.
    Ni Y; Xie X; Bu H; Zhang Z; Wei B; Yin L; Chen M; Chen H; Zhang H
    J Clin Pathol; 2013 Mar; 66(3):263-4. PubMed ID: 23172554
    [No Abstract]   [Full Text] [Related]  

  • 11. Cell membrane and cytoplasmic immunoreactivity of MIB-1 in invasive breast carcinoma.
    Ortiz-Rey JA; Peteiro A; Fernández-Costas A; Gómez de María C; Antón I
    Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):563-4. PubMed ID: 19620841
    [No Abstract]   [Full Text] [Related]  

  • 12. [Detection and treatment of ductal carcinoma of the breast].
    Semiglazov VV; Tabagua TT; Matsko DE
    Vopr Onkol; 2011; 57(6):699-701. PubMed ID: 22416383
    [No Abstract]   [Full Text] [Related]  

  • 13. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer.
    Hoque A; Menter DG; Sahin AA; Sneige N; Lippman SM
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):153-4. PubMed ID: 11219775
    [No Abstract]   [Full Text] [Related]  

  • 14. Is CD56 a specific and reliable neuroendocrine marker for discriminating between endocrine/neuroendocrine ductal carcinoma in situ and intraductal papilloma of the breast?
    Kawasaki T; Kondo T; Nakazawa T; Mochizuki K; Yamane T; Murata S; Inoue S; Tsunoda H; Katoh R
    Pathol Int; 2011 Jan; 61(1):49-51. PubMed ID: 21166944
    [No Abstract]   [Full Text] [Related]  

  • 15. An unusual triple-negative breast carcinoma.
    Shousha S; Peston D; Gojis O; Palmieri C
    Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
    Zhang R; Zhang H; Wei H; Luo X
    J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear grading in invasive ductal breast carcinomas.
    Kalogeraki A; Tamiolakis D; Kozoni V; Tzardi M; Panayiotides J; Melissas J; Zoras O; Tsiftsis D; Delides GS
    Cancer Detect Prev; 2000; 24(3):224-7. PubMed ID: 10975283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid sarcoma of the breast misdiagnosed as poorly differentiated mammary carcinoma with lobular features.
    Stewart RL; Dell CM; Samayoa L
    Breast J; 2015; 21(2):192-3. PubMed ID: 25583284
    [No Abstract]   [Full Text] [Related]  

  • 19. Invasive cystic hypersecretory ductal carcinoma of breast: a case report and review of the literature.
    Herrmann ME; McClatchey KD; Siziopikou KP
    Arch Pathol Lab Med; 1999 Nov; 123(11):1108-10. PubMed ID: 10539918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of breast cancer.
    Watkins EJ
    JAAPA; 2019 Oct; 32(10):13-17. PubMed ID: 31513033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.